Global Migraine Drugs Market Report 2024, By Drug Class (Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants), By Route of Administration (Oral, Injectable) and By En...
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Yahoo! Finance
The migraine drugs market size has grown strongly in recent years, from $5 billion in 2023 to $5.38 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth observed in the historical period can be attributed to various factors, including advancements in drug formulations, heightened awareness and diagnosis of migraines, the impact of stress and lifestyle factors on migraine prevalence, the expansion of generic drugs in the market, and the emergence of CGRP (calcitonin gene-related peptide) inhibitors as a notable treatment option. The migraine drugs market size is expected to see continued strong growth in the next few years, reaching $6.84 billion in 2028 at a CAGR of 6.2%. The anticipated growth in the forecast period can be attributed to several factors, including the adoption of personalized medicine approaches in migraine treatment, the increasing use of telemedicine and remote consultations for healthcare delivery, the influence of healthcare policy and in
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Non-Steroidal Anti-Inflammatory Drugs Market Size to Worth USD 33.55 Bn by 2032 [Yahoo! Finance]Yahoo! Finance
- Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- India's Alembic Pharma posts higher Q4 profit on strong N.America sales [Reuters]Reuters
- Dr. Reddy's Laboratories Limited (NYSE: RDY) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
- Dr. Reddy's Laboratories Limited (NYSE: RDY) had its price target raised by analysts at Barclays PLC from $80.00 to $81.00. They now have an "overweight" rating on the stock.MarketBeat
RDY
Earnings
- 5/8/24 - Beat
RDY
Sec Filings
- 5/17/24 - Form 6-K
- 5/15/24 - Form 6-K
- 5/13/24 - Form 6-K
- RDY's page on the SEC website